Bronchoalveolar Immune Response Determination

Extrinsic Allergic Alveolitis Clinical Trial

— BIRD  

Official title:

Study to Determine the Immune Response From Broncho-alveolar Cells Against Pigeon Specific Antigens

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01237145
• Other study ID #: BIRD01
• Status: Completed
• Phase: N/A
• First received: November 7, 2010
• Last updated: January 17, 2018
• Start date: September 2011
• Est. completion date: December 2012

Study information

• Verified date: January 2018
• Source: Bossink, A.W.J.
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to establish if cells present in lung tissue during extrinsic allergic alveolitis (EAA) are able to elicit an immune response against specific antigens. The hypothesis is: cells in BAL lavage fluid from patients with EAA will be responsive to specific antigens and this response can be measured using ELISPOT.

Description:

Subjects suffering from extrinsic allergic alveolitis caused by pigeons will undergo a broncho alveolar lavage. Cells obtained from this BAL will be used for ELISPOT technique with pigeon specific antigens

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: December 2012
• Est. primary completion date: September 2012
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• suspicion of pigeon induced extrinsic alveolitis

Exclusion Criteria:

• use of oral steroids

• unable to give informed consent

• age below 18

Related Conditions & MeSH terms

• Alveolitis, Extrinsic Allergic
• Extrinsic Allergic Alveolitis

Locations

Country	Name	City	State
Netherlands	Diakonessenhuis Utrecht	Utrecht

Sponsors (1)

Lead Sponsor	Collaborator
Bossink, A.W.J.

Country where clinical trial is conducted

Netherlands, 

References & Publications (3)

Jafari C, Thijsen S, Sotgiu G, Goletti D, Domínguez Benítez JA, Losi M, Eberhardt R, Kirsten D, Kalsdorf B, Bossink A, Latorre I, Migliori GB, Strassburg A, Winteroll S, Greinert U, Richeldi L, Ernst M, Lange C; Tuberculosis Network European Trialsgroup. Bronchoalveolar lavage enzyme-linked immunospot for a rapid diagnosis of tuberculosis: a Tuberculosis Network European Trialsgroup study. Am J Respir Crit Care Med. 2009 Oct 1;180(7):666-73. doi: 10.1164/rccm.200904-0557OC. Epub 2009 Jul 9. — View Citation

Kösters K, Nau R, Bossink A, Greiffendorf I, Jentsch M, Ernst M, Thijsen S, Hinks T, Lalvani A, Lange C. Rapid diagnosis of CNS tuberculosis by a T-cell interferon-gamma release assay on cerebrospinal fluid mononuclear cells. Infection. 2008 Dec;36(6):597-600. doi: 10.1007/s15010-007-7316-0. Epub 2008 Jan 12. — View Citation

Losi M, Bossink A, Codecasa L, Jafari C, Ernst M, Thijsen S, Cirillo D, Ferrarese M, Greinert U, Fabbri LM, Richeldi L, Lange C; European Tuberculosis Network TBNET. Use of a T-cell interferon-gamma release assay for the diagnosis of tuberculous pleurisy. Eur Respir J. 2007 Dec;30(6):1173-9. Epub 2007 Aug 22. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ELISPOT response in cells obtained from broncho-alveolar lavage	All elispots will be performed the same day, the end point will be available the next day	2 days
Secondary	Elispot response in cells from blood	ELispots will be performed the same day as blood collection, results will be available the next day	2 days